Back to Search
Start Over
Plasma-Methylated SEPT9 for the Noninvasive Diagnosis of Gastric Cancer
- Source :
- Journal of Clinical Medicine; Volume 11; Issue 21; Pages: 6399
- Publication Year :
- 2022
-
Abstract
- Background. Gastric cancer (GC) is one of the most prevalent cancers globally. This study was designed to evaluate the potential performance of plasma SEPT9 methylation (mSEPT9) as a noninvasive biomarker for the diagnosis of GC. Methods. A total of 182 participants, i.e., 60 patients with GC, 39 with chronic superficial gastritis (CSG), 27 with chronic atrophic gastritis (CAG), 30 with gastric ulcer (GU), and 26 with gastric polys (GP), were recruited. The mSEPT9 level was measured using real-time polymerase chain reaction. Results. As a diagnostic target, mSEPT9 (1/3 algorithm) had a sensitivity of 48.33 (95% confidence interval (CI): 35.40–61.48%) and a specificity of 86.89% (95% CI: 79.28–92.09%), and mSEPT9 (2/3 algorithm) had a sensitivity of 33.33 (95% CI: 22.02–46.79%) and a specificity of 98.36% (95% CI: 93.61–99.72%). The area under the receiver operating characteristic curve (ROC) curve of mSEPT9 was 0.698 (95% CI: 0.609–0.787) for the differentiation of GC from benign gastric diseases. The effectiveness of mSEPT9 (1/3 algorithm) was superior to that of CEA, CA19-9, and CA72-4. mSEPT9 was positively correlated with T, N, M, and the clinical stage of GC. Conclusions. Plasma mSEPT9 might serve as a useful and noninvasive biomarker for the diagnosis of GC.
- Subjects :
- General Medicine
diagnosis
DNA methylation
gastric cancer
SEPT9
Subjects
Details
- ISSN :
- 20770383
- Volume :
- 11
- Issue :
- 21
- Database :
- OpenAIRE
- Journal :
- Journal of clinical medicine
- Accession number :
- edsair.doi.dedup.....6164d7338b97cf7e0f8a82842ecee5fb